Differential Characteristics and Comparison Between Long-COVID Syndrome and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Ivanovska, Mariya, Homadi, Maysam Salim, Angelova, Gergana et al. · Biomedicines · 2025 · DOI
Quick Summary
This review compared Long-COVID (illness after COVID-19) and ME/CFS (chronic fatigue syndrome), which share similar symptoms like extreme tiredness, difficulty thinking clearly, and problems with the nervous system. While both conditions likely involve immune system problems, viral persistence, and blood vessel issues, they appear to have some differences in how they develop. Currently, there is no cure for either condition, though lifestyle management and rehabilitation help some people.
Why It Matters
Understanding similarities and differences between Long-COVID and ME/CFS could accelerate development of more effective treatments and diagnostic tools for both conditions. This comparison helps researchers identify which biological mechanisms are disease-specific versus shared, potentially revealing new therapeutic targets. For patients, clarifying these distinctions may improve diagnosis and personalized treatment strategies.
Observed Findings
- Both Long-COVID and ME/CFS are characterized by post-exertional malaise, cognitive impairment, autonomic dysfunction, and persistent fatigue.
- Both conditions appear to involve multiple overlapping pathophysiological mechanisms including viral persistence, immune dysregulation, endothelial dysfunction, and autoimmunity.
- Symptom management strategies are consistent between the two conditions, including cognitive behavioral therapy and pacing strategies.
- Graded exercise therapy remains contested, with recommendations shifting toward individualized pacing rather than standardized protocols.
- Minimal effective pharmaceutical treatments currently exist for either condition.
Inferred Conclusions
- Long-COVID and ME/CFS share substantial clinical and pathophysiological overlap but may have distinct features requiring separate investigation.
- Immune dysregulation represents a priority research target for understanding both conditions and developing therapeutics.
- Multidisciplinary, individualized rehabilitation approaches show more promise than standardized exercise protocols.
- Identifying disease-specific versus shared mechanisms is essential for developing targeted therapies.
Remaining Questions
- What are the specific pathophysiological differences between Long-COVID and ME/CFS, and do these account for their distinct epidemiologies?
- Which immune dysfunction mechanisms are primary drivers versus secondary consequences in each condition?
- Why do individualized pacing approaches appear more effective than standardized graded exercise therapy?
- What new pharmacological and biomarker-based diagnostic tools could improve treatment stratification for both conditions?
What This Study Does Not Prove
This review does not establish causation for any specific pathophysiological mechanism—it identifies associations reported in existing literature. It cannot determine whether Long-COVID and ME/CFS are fundamentally the same disease with different triggers or truly distinct conditions, as the relative contributions of overlapping mechanisms remain uncertain. The review does not provide new clinical trial data and cannot establish which treatments are most effective.
Topics
Tags
Metadata
- DOI
- 10.3390/biomedicines13112797
- PMID
- 41301889
- Review status
- Editor reviewed
- Evidence level
- Established evidence from major reviews, guidelines, or evidence maps
- Last updated
- 7 April 2026